U
ALNY icon

UBS’s Alnylam Pharmaceuticals ALNY Stock Holding History

UBS’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2.78M Sell
35,563
-37,793
-52% -$2.44M ﹤0.01% 2596
2014
Q2 		$4.63M Buy
73,356
+16,335
+29% +$971K ﹤0.01% 2032
2014
Q1 		$3.83M Buy
57,021
+18,691
+49% +$1.45M ﹤0.01% 2118
2013
Q4 		$2.46M Buy
38,330
+23,420
+157% +$1.4M ﹤0.01% 2592
2013
Q3 		$954K Buy
14,910
+10,649
+250% +$531K ﹤0.01% 3390
2013
Q2 		$132K Buy
+4,261
New +$113K ﹤0.01% 5553

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

UBS's ALNY Position: Q3 2014 in Review

UBS reduced its Alnylam Pharmaceuticals (ALNY) stake by 52% in Q3 2014, selling an estimated $2.44M and leaving 35,563 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

UBS first reported a position in ALNY in Q2 2013 and has held it in 6 quarters since. The position peaked at $4.63M in Q2 2014. 186 funds tracked by Wall St. Rank hold ALNY as of Q3 2014.

  • UBS held 35,563 shares of Alnylam Pharmaceuticals worth $2.78M as of Q3 2014.
  • UBS sold 37,793 Alnylam Pharmaceuticals shares in Q3 2014, an estimated $2.44M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2596 holding.
  • UBS first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Alnylam Pharmaceuticals position peaked at $4.63M in Q2 2014.
  • 186 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.